PGHL

Procter & Gamble Health Cash Flow

₹5,221.50-1.59%
Market cap
₹8,667 crore
P/E
24.3
P/B
16.52
ROE
61.5%
Dividend yield
1.72%

In the year ended Jun 2022, Procter & Gamble Health generated ₹170 crore from operating activities, invested ₹26 crore and paid out ₹289 crore on financing activities. Net cash flow for the year was -₹145 crore. Free cash flow was ₹132 crore.

Procter & Gamble Health cash flow statement

Financial years, newest first. Negative figures are cash outflows.

Procter & Gamble Health cash flows (₹ crore)
ItemJun 2022Jun 2023Jun 2024Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activities1702362281,4001,4001,4001,400338
Cash from investing activities-26-22-7-600-600-600-6001
Cash from financing activities-289-98-418-550-550-550-550-344
Net cash flow-145116-197250250250250-5
Capital expenditure————————
Free cash flow132194207950950950950322

Source: Company filings, in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Procter & Gamble Health cash flow — frequently asked questions

What is Procter & Gamble Health's operating cash flow?

Procter & Gamble Health's cash flow from operating activities was ₹170 crore in the year ended Jun 2022, fell 27.97% from ₹236 crore in Jun 2023.

What is Procter & Gamble Health's free cash flow?

Procter & Gamble Health's free cash flow — operating cash flow minus capital expenditure — was ₹132 crore in Jun 2022.

How much did Procter & Gamble Health spend on investing activities?

Net cash used in investing activities was ₹26 crore in Jun 2022. This covers capital expenditure, acquisitions and the purchase or sale of investments.

Same Data For Peers

Trade Procter & Gamble Health With ATS

Track PGHL live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.